Stephen Willey

In a report published Friday, Stifel analyst Stephen Willey reiterated a Buy rating on Genocea Biosciences (NASDAQ: GNCA), but lowered the price target from $29.00 to $24.00. In the report, Stifel noted, “GAAP net loss of $8.5M, or $(0.53)/share was wider than our/Consensus $(0.43)/(0.50) estimates...

In a report published Friday, Stifel analyst Stephen Willey reiterated a Buy rating on Dicerna Pharmaceuticals (NASDAQ: DRNA), but lowered the price target from $70.00 to $62.00. In the report, Stifel noted, “While emerging competitive concerns in PH1 have seemingly weighed on shares of late (...

In a report published Friday, Stifel analyst Stephen Willey reiterated a Buy rating on NewLink Genetics Corp (NASDAQ: NLNK), and raised the price target from $51.00 to $55.00. In the report, Stifel noted, “After recently-signing one of the most economically-significant P1 oncology transactions in...

In a report published Friday, Stifel analyst Stephen Willey initiated coverage on Applied Genetic Technologies Corporation (NASDAQ: AGTC) with a Buy rating and $29.00 price target. In the report, Stifel noted, “We are initiating coverage of Applied Genetic Technologies Corporation (AGTC) with a Buy...

In a report published Thursday, Stifel analyst Stephen Willey downgraded the rating on Theravance (NASDAQ: THRX) from Buy to Hold, and removed the $47.00 price target. In the report, Stifel noted, “We are viewing the recent post-split accretion in THRX shares as an opportunity to step to the...

In a report published Monday, Stifel analyst Stephen Willey initiated coverage on Dicerna Pharmaceuticals (NASDAQ: DRNA) with a Buy rating and $53.00 price target. In the report, Stifel noted, “We are initiating coverage on shares of Dicerna Pharmaceuticals Inc. (DRNA) with a Buy rating on the...

In a report published Friday, Stifel analyst Stephen Willey initiated coverage on Tekmira Pharmaceuticals (NASDAQ: TKMR) with a Buy rating and $19.00 price target. Willey noted that Tekmira is looking to capitalize on the growing “enthusiasm” for RNA interference (RNAi) based therapeutics by...

In a report published Friday, Stifel analyst Stephen Willey maintained Buy on InterMune (NASDAQ: ITMN), raising its price target from $20.00 to $23.00. According to the report, ITMN pre-announced a 4Q13 Esbriet beat and provided what appears to be fairly conservative FY14 Esbriet sales guidance...

In a report published Monday, Stifel analyst Stephen Willey initiated coverage on Ocera Therapeutics, Inc. (NASDAQ: OCRX) with a Buy rating and $19.00 price target. According to the report, OCRX’s lead product OCR-002 (ornithine phenylacetate) represents a best-in-class mechanism of action for...

In a report published Tuesday, Stifel analyst Stephen Willey initiated coverage on Relypsa (NASDAQ: RLYP) with a Buy rating and $25.00 price target. In the report, Stifel noted, “We are initiating coverage on shares of Relypsa, Inc. (RLYP) with a Buy rating and a 12-month target price of $25. We...

In a report published Tuesday, Stifel analyst Stephen Willey downgraded the rating on ViroPharma (NASDAQ: VPHM) from Buy to Hold, and removed the $47.00 price target. In the report, Stifel noted, “We are downgrading shares of Viropharma Inc. as a result of the company's recent announcement that...

In a report published Friday, Stifel analyst Stephen Willey terminated coverage on Onyx Pharmaceuticals (NASDAQ: ONXX). In the report, Stifel noted, “We are discontinuing coverage of Onyx Pharmaceuticals due to the company's acquisition by Amgen (AMGN, Covered by our Colleague Joel Sendek, Hold, $...

In a report published Friday, Stifel analyst Stephen Willey reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT), but lowered the price target from $16.00 to $13.00. In the report, Stifel noted, “GAAP net loss of $3.3M was roughly in-line with our $2.5M estimate – with slightly-higher...

In a report published Monday, Stifel analyst Stephen Willey initiated coverage on Ophthotech Corp. (NASDAQ: OPHT) with a Buy rating and $52.00 price target. In the report, Stifel noted, “We are initiating coverage on shares of Ophthotech Corp. (OPHT) with a Buy rating and a 12-month target price...

In a report published Wednesday, Stifel analyst Stephen Willey downgraded the rating on BioMarin Pharmaceutical (NASDAQ: BMRN) from Buy to Hold, and removed the $70.00 price target. In the report, Stifel noted, “We are downgrading shares of BioMarin from Buy to Hold – despite yesterday's largely...